Advertisement

U.S. markets open in 1 hour 53 minutes

S&P Futures
4,275.50
-32.25(-0.75%)
Dow Futures
33,927.00
-191.00(-0.56%)
Nasdaq Futures
13,534.50
-123.75(-0.91%)
Russell 2000 Futures
2,007.10
-16.20(-0.80%)
Crude Oil
86.35
-0.18(-0.21%)
Gold
1,782.20
-7.50(-0.42%)

Advertisement

Axcella Health Inc. (AXLA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Add to watchlist

2.7300

+0.0800

(+3.02%)

At close: 04:00PM EDT

2.7700

+0.04

(+1.47%)

After hours:

06:58PM EDT

Advertisement

Loading interactive chart...

Business Wire
Axcella Reports Second Quarter Financial Results and Provides Business Update
CAMBRIDGE, Mass., August 12, 2022--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the second quarter ended June 30, 2022 and provided a business update.
Zacks
The Zacks Analyst Blog Highlights Absci Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics
Absci, Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics are part of Zacks top Analyst Blog.
Zacks
5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.

Advertisement